26 terminated. 26 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 26 | Terminated 26 |
| Phase 2 | 8 | Terminated 8 |
Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis OTC Drug for Atopic Dermatitis in Cream form - Atopic Dermatitis (AD) | Phase 1 | Terminated | Good Molecules, LLC | 3 | 2025-08-14 | 2026-05-27 |
| Topical ENS-002 for Atopic Dermatitis in Adults ENS-002 - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 1 | Terminated | Concerto Biosciences | 9 | 2024-09-18 | 2025-08-14 |
| A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis LY3872386, Prednisone, Placebo - Healthy, Atopic Dermatitis | Phase 1 | Terminated | Eli Lilly and Company | 18 | 2023-11-01 | 2025-10-03 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Placebo, IMG-007 - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | Phase 1 / Phase 2 | Terminated | Inmagene LLC | 13 | 2023-08-09 | 2025-11-06 |
| Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD) NM26-2198, Placebo - Atopic Dermatitis | Phase 1 | Terminated | Yellow Jersey Therapeutics AG | 126 | 2023-05-10 | 2026-07-06 |
| Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ) Dermaprazole 1%, Dermaprazole 2% - Radiation Dermatitis, Breast Cancer | Phase 1 / Phase 2 | Terminated | Baylor College of Medicine | 3 | 2023-04-24 | 2026-02-17 |
| Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis XmAb27564, Placebo - Psoriasis, Atopic Dermatitis | Phase 1 | Terminated | Xencor, Inc. | 23 | 2022-10-10 | 2025-12-02 |
| A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis LY3844583, Placebo - Healthy, Dermatitis, Atopic | Phase 1 | Terminated | Eli Lilly and Company | 86 | 2022-08-11 | 2026-10-13 |
| Targeted Investigation of Microbiome Elimination S. hominis A 9 Product, Placebo - Atopic Dermatitis | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 21 | 2022-07-18 | 2024-11-12 |
| A Study of Orally Administered IPG7236 in Healthy Adult Participants IPG7236- Single ascending dose, IPG7236- Multiple ascending dose, Placebo (Part A) - Atopic Dermatitis | Phase 1 | Terminated | Nanjing Immunophage Biotech Co., Ltd | 63 | 2022-04-07 | 2025-12-22 |
| A Study for AR100DP1 in Mild to Moderate Atopic Dermatitis (AD) AR100DP1 - Dermatitis, Atopic | Phase 1 / Phase 2 | Terminated | Arjil Pharmaceuticals LLC | 17 | 2020-12-08 | 2023-12-11 |
| A Non-Drug Study Detecting And Quantifying Nocturnal Scratch Behaviors From Wrist Actigraphy Data In Adult Healthy Volunteers And Participants With Atopic Dermatitis (AD) Wrist Actigraphy Device, Sleep Headband - Atopic Dermatitis | Phase 1 | Terminated | AbbVie | 16 | 2020-02-17 | 2022-02-15 |
| Phase I Study of DS-2741a in Healthy Volunteers and Participants With Atopic Dermatitis DS-2741a, Placebo - Atopic Dermatitis | Phase 1 | Terminated | Daiichi Sankyo Co., Ltd. | 8 | 2020-01-13 | 2021-06-22 |
| Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Clobetasol propionate 0.05% Topical Oil - Atopic Dermatitis | Phase 1 / Phase 2 | Terminated | Hill Dermaceuticals, Inc. | 8 | 2019-09-09 | 2021-06-23 |
| Study of KHK 4323 in Healthy Volunteers and Subjects With Atopic Dermatitis KHK4323 IV/S, KHK4323 SC/S, KHK4323 IV/M - Atopic Dermatitis | Phase 1 | Terminated | Kyowa Kirin Co., Ltd. | 5 | 2019-02-22 | 2020-01-28 |
| A Study to Test Safety, Tolerability, and the Way the Body Absorbs, Distributes, and Gets Rid of a Study Drug Called MOR106, in Healthy Subjects and in Patients With Moderate to Severe Atopic Dermatitis MOR106, Placebo - Healthy, Atopic Dermatitis | Phase 1 | Terminated | Lakefront Biotherapeutics NV | 44 | 2018-08-13 | 2020-03-18 |
| Topical Use of Difinsa53™ to Prevent Radiation Dermatitis Difinsa53, Aquaphor - Radiodermatitis | Phase 1 / Phase 2 | Terminated | ProTechSure Scientific, Inc. | 13 | 2015-08-01 | 2017-10-06 |
| A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003) MK-8226, Placebo - Atopic Dermatitis | Phase 1 | Terminated | Merck Sharp & Dohme LLC | 65 | 2012-12-21 | 2019-03-15 |
| Study to Assess the Clinical Activity of a Sequential Dose of REGN846 on Refractory Pruritus in Patients With Atopic Dermatitis REGN846 - Pruritus, Atopic Dermatitis | Phase 1 / Phase 2 | Terminated | Regeneron Pharmaceuticals | 19 | 2012-06-01 | 2013-10-28 |
| Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. LEO 29102, LEO 29102 Cream Vehicle - Atopic Dermatitis | Phase 1 | Terminated | LEO Pharma | 58 | 2011-09-01 | 2025-02-24 |
Showing 20 of 26. Sign in to see all of them.
Dermatitis, Atopic (20) · Eczema (4) · Radiodermatitis (4) · Alopecia (2) · Breast Neoplasms (2) · Psoriasis (2) · Skin Diseases (2) · Anus Neoplasms (1) · Head and Neck Neoplasms (1) · Immune System Diseases (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Pruritus (1) · Stevens-Johnson Syndrome (1)
Skin and Connective Tissue Diseases (26) · Skin Diseases (24) · Hypersensitivity (21) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (20) · Genetic Diseases, Inborn (20) · Hypersensitivity, Immediate (20) · Immune System Diseases (20) · Skin Diseases, Eczematous (20) · Skin Diseases, Genetic (20) · Neoplasms (5) · Neoplasms by Site (4) · Radiation Injuries (4) · Wounds and Injuries (4) · Pathological Conditions, Signs and Symptoms (3)
Norepinephrine (2) · 2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide (1) · Clobetasol (1) · Fibroblast Growth Factor 7 (1) · Fluorouracil (1) · Interleukin 1 Receptor Antagonist Protein (1) · Mitomycin (1) · Nonprescription Drugs (1) · Oils (1) · Petrolatum (1) · Prednisone (1) · Radiotherapy (1) · dimethicone (1) · tempol (1)
Eli Lilly and Company (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · ProCertus BioPharm, Inc (2) · AbbVie (1) · Arjil Pharmaceuticals LLC (1) · Baylor College of Medicine (1) · Brett King (1) · Concerto Biosciences (1) · Daiichi Sankyo Co., Ltd. (1) · Good Molecules, LLC (1) · Hill Dermaceuticals, Inc. (1) · Inmagene LLC (1) · Kyowa Kirin Co., Ltd. (1) · LEO Pharma (1) · Lakefront Biotherapeutics NV (1)
United States (18) · Germany (4) · Canada (3) · Japan (3) · Poland (2) · Australia (1) · Finland (1) · Spain (1) · Taiwan (1) · Ukraine (1) · United Kingdom (1)
Bernardo Cervantes, PhD (1) · Bethany M Anderson, MD (1) · Daniel A Hamstra, MD, PhD (1) · Deborah E Citrin, M.D. (1) · Diamant Thaci, MD (1) · Helen Timmis, MB CHB (1) · James F Cleary, MBBS (1) · John J Voorhees, MD (1) · Joshua D Milner, M.D. (1) · Joshua Petit, MD (1)
2018 (1), 2023 (1)